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The International Hypoglycaemia Study Group recom-
mends that the frequency of detection of a glucose con-
centration <3.0 mmol/l (<54 mg/dl), which it considers
to be clinically significant biochemical hypoglycaemia,
be included in reports of clinical trials of glucose-
lowering drugs evaluated for the treatment of diabetes
mellitus.
The glycaemic thresholds for symptoms of hypoglycaemia
and for glucose counterregulatory (including sympathoadrenal)
responses to hypoglycaemia, as plasma glucose concentrations
fall, are not fixed in patients with insulin-, sulfonylurea- or
meglitinide- (glinide)-treated diabetes. They are at higher glu-
cose concentrations in those with poor glycaemic control and at
lower glucose concentrations in those with tight glycaemic con-
trol [1–5]. The shifts in glycaemic threshold to lower glucose
concentrations are largely the result of more frequent episodes
of iatrogenic hypoglycaemia during intensive glycaemic thera-
py. Glycaemic thresholds for responses to hypoglycaemia vary,
not only among individuals with diabetes but also in the same
individual with diabetes as a function of their HbA1c levels and
hypoglycaemic experience; it is therefore not appropriate to cite
a specific glucose concentration that defines hypoglycaemia in
diabetes. As a consequence, the American Diabetes
Association has defined hypoglycaemia in diabetes non-
numerically as ‘all episodes of an abnormally low plasma glu-
cose concentration that expose the individual to potential harm’
[6, 7].
Nonetheless, the International Hypoglycaemia Study
Group believes that it is important to identify and re-
cord a level of hypoglycaemia that needs to be avoided
because of its immediate and long-term danger to the
individual. A single glucose level should be agreed to
that has serious clinical and health-economic conse-
quences. This would enable the diabetes and regulatory
communities to compare the effectiveness of interven-
tions in reducing hypoglycaemia, be they pharmacolog-
ical, technological or educational. It would also permit
the use of meta-analysis as a statistical tool to increase
power when comparing interventions.
In its discussion, the International Hypoglycaemia
Study Group considered glucose concentration levels
of <3.0 mmol/ l (<54 mg/dl) and <2.8 mmol/ l
(<50 mg/dl) detected by self-monitoring of plasma glu-
cose, continuous glucose monitoring (for at least
20 min) or a laboratory measurement of plasma glucose.
Both of these levels are distinctly low glucose concen-
trations that do not occur under physiological conditions
in non-diabetic individuals [8]. Thus, they are unequiv-
ocally hypoglycaemic values. They approximate the up-
per and lower limits, respectively, of the non-diabetic
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glycaemic threshold for symptoms of insulin-induced
hypoglycaemia [8–10]. The generic non-diabetic
glycaemic threshold for impairment of cognitive func-
tion is <2.8 mmol/l [8–10], but higher glucose levels
have been reported for some tests [11–14]. Glucose con-
centrations of both <3.0 mmol/l and <2.8 mmol/l cause
defective glucose counterregulation and impaired aware-
ness of hypoglycaemia, the core components of
hypoglycaemia-associated autonomic failure in diabetes
[5]. Avoiding these glucose levels could reverse im-
paired awareness of hypoglycaemia [15–18] and some
aspects of defective glucose counterregulation [15–17]
in many affected patients. In type 1 diabetes, failure to
recognise one’s own hypoglycaemia at a glucose con-
centration <3.0 mmol/l increased the risk of severe
hypoglycaemia (defined as needing the help of another
person for recovery) fourfold [17]. In type 2 diabetes,
both glucose concentrations were associated with cardi-
ac arrhythmias [19, 20]. Finally, a glucose concentration
<2.8 mmol/l was associated with mortality in patients
with type 2 diabetes in the Action to Control
Cardiovascular Risk in Diabetes (ACCORD) trial
(NCT00000620) [21], and possibly in the Outcomes
Reduction with an Initial Glargine Intervention
(ORIGIN) trial (NCT00069784) [22] and among pa-
t i en t s t r e a t ed in i n t ens ive ca r e un i t s i n the
Normoglycemia in Intensive Care Evaluation—Survival
Using Glucose Algorithm Regulation (NICE-SUGAR)
trial (NCT00220987) [23]. A glucose concentration
<3.0 mmol/l was associated with mortality in the
NICE-SUGAR trial [23] and, possibly, in the ORIGIN
trial [22].
Ultimately, the International Hypoglycaemia Study
Group members agreed that a glucose concentration
<3.0 mmol/l (<54 mg/dl) is sufficiently low to indicate
serious, clinically important hypoglycaemia. Possible
t e rms used to desc r ibe th i s cond i t ion inc lude
‘serious’, ‘clinically important’, ‘major’ or ‘clinically sig-
nificant’. The group decided not to describe ‘severe
hypoglycaemia’ in terms of glucose concentration since
there is currently widespread agreement that severe
hypoglycaemia, as defined by the American Diabetes
Association [6, 7], denotes severe cognitive impairment
requiring external assistance for recovery. The group also
proposed that the frequency of detection of the glucose
alert value of 3.9 mmol/l (70 mg/dl) or less [24] need
not be reported routinely in clinical trials.
In conclusion we propose that the following glucose levels
be adopted by the diabetes community to address the issue of
hypoglycaemic risk (text box).
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